Bridget Walton
Vice President, GRA
Principal Consultant
Bridget Walton, MS, is an accomplished global regulatory affairs strategist with over 25 years of experience across all stages of drug development. With specialized expertise in neurology, psychiatry, ophthalmology, and Schedule I and II controlled substances, Bridget is known for her strategic vision, executional focus, and ability to lead high-performing teams.
As Vice President and Global Head of Regulatory Affairs at a pioneering biotech firm, she spearheaded regulatory strategies for innovative psychedelic therapies and a Software as a Medical Device (SaMD) product. Previously, at Sunovion Pharmaceuticals, Bridget held progressive leadership roles, driving regulatory strategies for CNS products, including leading successful INDs/CTAs, NDAs, and MAAs. Her leadership was pivotal in securing the first-cycle U.S. approval of Latuda® and facilitating its global commercialization.
Bridget's mastery of global regulatory frameworks, innovative thinking, and collaborative approach make her a trusted leader in advancing therapeutic innovations while ensuring compliance and operational excellence.
She holds an MS in Molecular Biology from Villanova University and an MS in QA/RA from Temple University.
